Net Present Value Impact of FDA’s Phase 3 Waivers on Monoclonal Antibody Biosimilar Development

Phase 3 waivers can substantially reduce development costs (~$25M average), accelerate timelines (~1.5 years), and improve NPV (~25-29%) for well-characterized monoclonal antibody biosimilars meeting FDA's analytical similarity and pharmacokinetic equivalence criteria. Economic benefits are conditional on robust analytical data, regulatory approval of waiver requests, and appropriate product selection (Tier 1/2/3 classification). Real-world realization requires post-implementation surveillance of FDA approval patterns, achieved cost reductions, and timeline compression beginning 2026-2027.